General pharmacology of Meloxicam - Part II: Effects on blood pressure, blood flow, heart: Rate, ECC, respiratory minute volume and interactions with paracetamol, pirenzepine, chlorthalidone, phenprocoumon and tolbutamide

General Pharmacology

Volumn 27, Issue 4, 1996, Pages 679-688

  Engelhardt, G ^a   Homma, D ^a   Schlegel, K ^a   Schnitzler, Chr ^a   Utzmann, R ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Meloxicam; NSAIDs; Pharmacodynamics; Pharmacology

Indexed keywords

CHLORTALIDONE; MELOXICAM; PARACETAMOL; PHENPROCOUMON; PIRENZEPINE; TOLBUTAMIDE;

ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE; CAT; CONTROLLED STUDY; DRUG EFFECT; ELECTROCARDIOGRAM; HEART RATE; INFLAMMATION; LUNG MINUTE VOLUME; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

EID: 0030176264     PISSN: 03063623     EISSN: None     Source Type: Journal    
DOI: 10.1016/0306-3623(95)02035-7     Document Type: Article

References (40)

1. BGA (1988) Erläuterungen des BGA zum Antrag auf Zulassung eines Arzeimittels, 2 Aufl, 26.02. 1988.
2. Brater D. C., Anderson S., Baird B. and Campbell W. B. (1985) Effects of ibuprofen, naproxen and sulindac on prostaglandins in men. Kidney Int. 27, 66-73.
3. 14C-labelled meloxicam: a new antiphlogistic drug, in man. Abstract presented at the XVIItk ILAR Congress of Rheumatology, Rio de Janeiro, Brazil, 17-23 September 1989. Brasil, Soc. Rheumatol., Campinas, 190 p.
4. Busch U. (1994) Pharmacokinetics of meloxicam in animals. Scand. J. Rheumatol. Suppl. 98, (abstr.) 119.
5. Capetola R. J. and McGuire J. L. (1980) Analgesic composition. European Patent Application NO 79 30 29 15.8, date 9.7.1980.
6. Christensen L.K., Hansen J.M. and Kristensen M. (1963) Sulphaphenazole-induced hypoglycaemic attacks in tolbutamide-treated diabetics. Lancet II, 1298-1301.
7. Clive D. M. and Stoff J. S. (1984) Renal syndromes associated with nonsteroidal anti-inflammatory drugs. N. Engl. J. Med. 310, 563-572.
8. Commission of the European Communities. (1993) Notice to Applicants for Marketing Authorization for Medicinal Products for Human Use in the Member States of the European Community, Vol. IIA 1993, July 1993.
9. Doepfner W. and Cerletti A. (1958) Comparison of lysergic acid derivatives and antihistamines as inhibitors of the edema provoked in the rat's paw by serotonin. Int. Arch. Allergy Appl. Immunol. 12, 90-97.
10. Dunn M. J. (1984) Non-steroidal anti-inflammatory drugs and renal function. Annu. Rev. Med. 35, 411-428.
11. Eisen M. J. (1964) Combined effect of sodium warfarin and phenylbutazone. J. Am. Med. Assoc. 189, 64-65.
12. Engelhardt G. (1984) Tiere experimentelle Untersuchungen zur Frage des Zusammenwirkens von Paracetamol und Acetylsalicylsäure. Arzneim.-Fonch. 34, 992-1101.
13. Engelhardt G. (1994a) Meloxicam, a potent inhibitor of adjuvant arthritis in the rat. Scand. J. Rheumatol. Suppl. 98, (abstr.) 110.
14. Engelhardt G. (1994b) Meloxicam. A potent inhibitor of COX-2. 9th International Conference on prostaglandins and related compounds, Florence (Italy), June 6-10, 1994, (abstr.) Giovanni Lorenzini, Milan, p. 82.
15. Engelhardt G., Homma D., Schlegel K., Schnitzler CHR. and Utzman R. (1995) Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent, Inflamm. Res. 44, 423-433.
16. Engelhardt G. (1996) Influence of meloxicam on arachidonic acid metabolism. Biochem. Pharmacol. 51, 21-38.
17. Food and Drugs Administration. (1987) Guidelines for the format and the content of the nonclinical/pharmacology/toxicology section of an applicant. Rockville, Maryland, February 1987.
18. Fieller E. C. (1944) A fundamental formula in the statistics of biological assay, and some applications. Q. J. Pharm. Pharmac. 17, 117-123.
19. Finney D. J. (1971) Probit Analysis. 3rd ed, Cambridge University Press, Cambridge.
20. Fleisch A. (1925) Der Pneumotachograph, ein Apparat zur geschwindigkeits-registrierung der atemluft. Pflüger's Arch. Ges. Physiol. Mensch. Tiere 209. 713-720.
21. Gardocki J. F. (1980) Analgesic composition comprising acetaminophen as a potentiating agent. European Patent Application NO. 79 30 29 14.1, 25.06.1980. EP12621.
22. Hucker H. B., Zacchei A. G., Cox S. V., Brodie D. A. and Cantwell N. H. R. (1966) Studies on the absorption, distribution and excretion of indomethacin in various species. J. Pharmacol. Exp. Ther. 153, 237-242.
23. Japanese Guidelines for general pharmacological studies. MWH January 1991.
24. Japanese Guidelines for general pharmacological studies. MHW January 1991. Judis J. (1972) Binding of sulfonylureas to serum proteins. J. Pharm. Sci. 61, 89-93.
25. Koelzer P. and Wehr H. (1958) Beziehungen zwischen chemischer Konstitution und pharmakologischer Wirkung bei mehreren Klassen neuer Lokalanaesthetika. Arzneim.-Forsch. 8, 181-190.
26. Leithold M. and Engelhorn R. (1977) Pharmakologische Prüfung der magensekretionshemmnenden Wirkung von 5, 11-Dihydro-11-]4-methyl-piperazin-1-yl)acetyl]-6-H-pyridol[2,3-b][1,4] benzodiazepin-6-on-dihydrochlorid (LS 519). Therapiewoche 27, 1517-1531.
27. Linder A. (1964) Statistische Methoden. 4th ed, pp. 148-162. Birkhäuser, Basel.
28. Martinek J. M. D. (1979) Pharmacological profile of the combination tolmetin and acetaminophen. Int. J. Tissue React. 1, 211-216.
29. Oates J. (1988) Antagonism of antihypertensive drug therapy by non-steroidal anti-inflammatory drugs. Hypertension 11, (Suppl. II), 114-116.
30. Radack K. C., Deck C. C. and Bloomfield S. S. (1987) Ibuprofen interferes with the efficacy of anti-hypertensive drugs. Ann. Int. Med. 107, 628-635.
31. Randall L. O. and Selitto J. J. (1957) A method for measurement of analgesic activity on inflammation tissue. Arch. Int. Pharmacodyn. Ther. 111, 409-419.
32. Sahloul M. Z., Al-Kick R., Ivanovich P. and Mujais S. K. (1990) Non-steroidal anti-inflammatory drugs and antihypertensives. Nephron. 56, 345-352.
33. Seegers A. J. M., Jager L. P., Zandberg P., Van Noordwijk J. (1981) The anti-inflammatory, analgesic and antipyretic activities of non-narcotic analgesic drug mixtures in rats. Arch. Int. Pharmacodyn. Ther. 251, 237-254.
34. Seyberth H. W. (1987) Die bedeutung der renalen prostaglandine für die nierenfunktion im frühen kindesalter. Monatsschr. Kinderheilkd. (Berlin) 135, 178-184.
35. Sörgel F., Krakau J., Lang E., Braun J. and Gensler U. (1985) The effects of indomethacin, ketoprofen and piroxicam on basal and furosemid-induced sodium excretion in the healthy subject. In Side-effects of Anti-inflammatory Drugs, (Edited by Rainsford K. D. and Velo G. P). MTP Press, Lancaster-Boston-The Hague-Dordrecht.
36. Stacher G., Bauer P., Ehn I. and Schreiber E. (1979) Effects of tolmetin, paracetamol, and of two combinations of tolmetin and paracetamol as compared to placebo on experimentally induced pain. A double blind study. Int. J. Clin. Pharmac. Biopharm. 17, 250-255.
37. Weinblatt M. E. (1989) Drug interactions with non-steroidal anti-inflammatory drugs (NSAIDs). Scand. J. Rheumatol. 83, (Suppl.) 7-10.
38. Werner W., Rey H. G. and Wielinger H. (1970) Über die eigenschaften eines neuen chromogens für die blutzuckerbestimmung nach der GOD/POD-methode. Zeitschrift. Anal. Chan. 252, 224-228.
39. Winter C. A., Risley E. A. and Nuss G. W. (1962) Carrageenin-induced edema in hind paw of the rat as an assay for antiinflammatory drugs. Proc. Soc. Exp. Biol. 111, 544-547.
40. Wong S. and Gardocki J. F. (1983) Anti-inflammatory and antiarthritic evaluation of acetaminophen and its potentiation of tolmetin. J. Pharmac. Exp. Ther. 226, 625-632.